MDxHealth, Inc. Opens New Service And Research Laboratory In The Netherlands
Published: Oct 05, 2017
HERSTAL, BELGIUM - 07:00 CEST, October 5, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the opening of its new service and research laboratory at the Novio Tech Campus in Nijmegen, the Netherlands.
MDxHealth has leased 700 square meters of prime mixed-use facilities at the Novio Tech Campus, a health-tech corporate park that, together with Radboudumc, supports emerging growth and multi-national companies at the intersection of technology and life sciences. MDxHealth has completed build-out and certification of its state-of-the-art laboratory facilities in Nijmegen, significantly expanding our capacity and infrastructure to perform our SelectMDx® for Prostate Cancer test, as well as ongoing research, development and commercial activities.
"After the acquisition of Noviogendix in 2015, and the successful launch of the Company's urine-based prostate cancer test, SelectMDx in early 2016, we've more than doubled our laboratory operations staff," commented Dr. Jan Groen, CEO, MDxHealth. "We also have doubled our European sales force in order to support the growth of our in vitro diagnostic uro-oncology business world-wide."
To mark the occasion, Michiel Scheffer, PhD, Member of the Executive Board of the Province Gelderland and Prof dr. Jack A. Schalken, Radboudumc Research Director of Urology, will speak at the headquarters' opening ceremony at 15:00 this afternoon alongside MDxHealth executives and board members.
MDxHealth's new laboratory facility is located at:
Novio Tech Campus
6534 AT Nijmegen
The Company's corporate office and registered address is in Herstal, Belgium.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Nijmegen, the Netherlands and US headquarters are in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Shalon Roth, EVP, Corporate Communications & Public Affairs
+44 (0)7393 906278
This company announcement contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this announcement to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This company announcement does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.Attachments: